Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

Acne

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

J Am Acad Dermatol.

Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP

doi: 10.1016/j.jaad.2018.06.046.

The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls

JAMA Dermatol.

Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, Larsen N, Andersen LO, Nielsen HV, Miller IM, Bjarnsholt T, Fuursted K, Jemec GB

doi: 10.1001/

Acne

The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction

J Invest Dermatol.

Witte-Händel E, Wolk K, Tsaousi A, Irmer ML, Mößner R, Shomroni O, Lingner T, Witte K, Kunkel D, Salinas G, Jodl S, Schmidt N, Sterry W, Volk HD, Giamarellos-Bourboulis EJ, Pokrywka A, Döcke WD, Schneider-Burrus S, Sabat R

doi: 10.1016/j.jid.2018.11.018.

Acne

Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study

J Eur Acad Dermatol Venereol

Hafner A, Ghislain PD, Kovács R, Batchelor R, Katoulis AC, Kirby B, Banayan H, Schonbrun M

doi: 10.1111/jdv.17551

Acne

Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data

J Am Acad Dermatol.

Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG

doi: 10.1016/j.jaad.2019.12.044.

Acne

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

J Eur Acad Dermatol Venereol

Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C

doi: 10.1111/jdv.17598

Acne

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial

JAMA Dermatol

Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S, Baeten D, Ionescu L, Zouboulis CC, Shaw S

doi: 10.1001/jamadermatol.2021.2905

Acne

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

J Am Acad Dermatol.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE

doi: 10.1016/j.jaad.2018.05.040.

Acne

Potential Predictive Biomarkers of Adalimumab Response in Patients with Hidradenitis Suppurativa

Br J Dermatol

Cao Y, Hong F, Conlon DM, Sidur L, Smith KM, Fang Y, Cuff CA, Kaymakcalan Z, Ruzek MC

doi: 10.1111/bjd.20097

Related content

Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls

The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction

Improvement in Hidradenitis Suppurativa and Quality of Life in Patients Treated With Adalimumab: Real-World Results From the HARMONY Study

Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data

Real-world effectiveness of adalimumab in patients with moderate to severe hidradenitis suppurativa: The 1-year SOLACE study

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Potential Predictive Biomarkers of Adalimumab Response in Patients with Hidradenitis Suppurativa